Clastogens are potential human carcinogens whose detection by genotoxicity assays is important for safety assessment. Although some endogenous genes are sensitive to the mutagenicity of clastogens, many genes that are used as reporters for in vivo mutation (e.g. transgenes) are not. In this study, we have compared responses in the erythrocyte Pig-a gene mutation assay with responses in a gene mutation assay that is relatively sensitive to clastogens, the lymphocyte Hprt assay, and in the reticulocyte micronucleus (MN) assay, which provides a direct measurement of clastogenicity. Male F344 rats were treated acutely with X-rays, cyclophosphamide (CP) and Cis-platin (Cis-Pt), and the frequency of micronucleated reticulocytes (MN RETs) in peripheral blood was measured 1 or 2 days later. The frequencies of CD59-deficient Pig-a mutant erythrocytes and 6-thioguanine-resistant Hprt mutant T-lymphocytes were measured at several times up to 16 weeks after the exposure. All three clastogens induced strong increases in the frequency of MN RETs, with X-rays and Cis-Pt producing near linear dose responses. The three agents also were positive in the two gene mutation assays although the assays detected them with different efficiencies. The Pig-a assay was more efficient in detecting the effect of Cis-Pt treatment, whereas the Hprt assay was more efficient for X-rays and CP. The results indicate that the erythrocyte Pig-a assay can detect the in vivo mutagenicity of clastogens although its sensitivity is variable in comparison with the lymphocyte Hprt assay.
Introduction
A novel assay has been developed that uses the endogenous X-linked phosphatidylinositol glycan, class A gene (Pig-a in rodents and PIG-A in humans) as a reporter of in vivo mutation (1) (2) (3) (4) (5) . The original concept for the assay was proposed by Araten and colleagues (6) as a side application of a clinical test for the rare human acquired genetic disorder, paroxysmal nocturnal hemoglobinuria (PNH) (7) (8) (9) . The Pig-a gene codes for an enzyme involved in the synthesis of glycosyl phosphatidylinositol (GPI). GPI anchors specific protein markers to the exterior side of the cytoplasmic membrane in mammalian cells, including cells of the hematopoietic system. A single inactivating mutation in the Pig-a gene can disrupt GPI synthesis and cause a deficiency of surface bound GPIanchored markers. In the assay, Pig-a mutant cells, deficient in GPI-anchored markers, are distinguished from wild-type cells and quantitated using immunophenotypic staining with antibodies to the markers and subsequent analysis on a flow cytometer.
This approach for measuring Pig-a mutation works exceptionally well for detecting mutation in the peripheral blood erythrocytes of rats and mice exposed to potent gene mutagens, such as N-ethyl-N-nitrosourea, benzo [a] pyrene, N-methyl-Nnitrosourea, 7,12-dimethylbenz[a]anthracene and 4-nitroquinoline-N-oxide (10) (11) (12) (13) (14) (15) (16) (17) . In fact, several variants of the red blood cell (RBC) Pig-a assay have been developed, with some promising substantial improvements to the sensitivity and throughput of the assay (18, 19) . In general, it appears that the assay may be a useful tool for measuring gene mutation in vivo, e.g. for the preclinical safety assessment of drugs and for monitoring the genotoxic load in humans (20, 21) .
One of the major considerations in developing any new genotoxicity assay, however, is determining its strengths and weaknesses, including any limitations on the types of compounds it is sensitive to. Until recently, there has been little information on the performance of the Pig-a-based model for the detection of mutation caused by clastogens and aneugens, which primarily cause chromosome breaks or alter chromosome number. Historically, gene mutation models have exhibited varying degrees of sensitivity to these types of agents, with many of the transgenic gene mutation models being notably insensitive, and endogenous reporters, such as the lymphocyte Hprt gene, being more sensitive (22) (23) (24) .
Preliminary reports on the detection of mutation in human cancer patients treated with radiotherapy or antineoplastic drugs suggest that the RBC PIG-A model is not very efficient in detecting mutation induced by clastogens such as X-rays and cyclophosphamide (5, 6) . There may be a reason why PIG-A is not a sensitive reporter of mutation in humans (e.g. due to specific elimination of mutant RBCs by human compliment system) (25, 26) ; but additional biological constraints may be imposed on the gene (in humans and in other species) when detecting mutations caused by clastogens. In this study, we determined RBC Pig-a mutant frequencies (MFs) in rats exposed acutely to three potent clastogens, X-rays, cyclophosphamide (CP) and Cis-platin (Cis-Pt). We compared the sensitivity of detecting treatment-induced effects in the erythrocyte Pig-a-based gene mutation model with the Hprt-based model for detecting mutation in spleen T cells and the micronucleus (MN) test in peripheral blood erythrocytes, an assay that directly measures the clastogenic and aneugenic effects of the treatments. During the course of these studies, which began with our initial observations on humans treated with cancer chemotherapeutic agents (5), technical aspects of the Pig-a assay have evolved rapidly. Thus, our first studies on X-ray-treated rats involved basic, relatively straightforward, and, by today's standards, relatively low throughput assays, whereas the most recent studies on Cis-Pt-treated rats employed the latest magnetic enrichment protocols.
Materials and methods

Animals and treatments
All animal procedures were reviewed and authorised by the National Center for Toxicological Research (NCTR) Institutional Animal Care and Use Committee. Eight-week-old F344 male rats from the NCTR breeding colony were exposed to X-rays in a calibrated RS200 irradiator (RadSource, Atlanta, GA) at timed intervals. Animals (either individually or in pairs) were irradiated with equally fractionated doses on three consecutive days to achieve final total doses of 1 Gy, 2 Gy and 3 Gy. The control group was not exposed. The time line for the key events of the experiment is shown in Figure 1 . The day of the last irradiation was designated as the 'Day 0' time point.
CP (Isopack monohydrate, Sigma-Aldrich, St Louis, MO) was dissolved in neutral phosphate-buffered saline (PBS) at 5 mg/ml or 20 mg/ml, sterilised using 0.2-μm filter, and, within 1 h, delivered intra peritoneally (i.p.) in a single dose to groups of 8-week-old F344 male rats at 10, 40 or 80 mg/kg (from 0.3 to 1 ml of the appropriate stock solution). In the control group, animals were injected i.p. with 0.7 ml of the vehicle, PBS. The day of treatment was designated as the "Day 0" time point.
Stock solutions (0.5 and 1 mg/ml) of Cis-Pt (Sigma-Aldrich) were prepared by vigorous shaking in 0.9% NaCl. Yellow/brown powdery Cis-Pt completely dissolved into a clear, slightly yellowish liquid, which was filter sterilised. The stocks were administered to 8-week-old male F344 rats intravenously (i.v.) via the tail vein in volumes of 0.2-0.5 ml, giving doses of 0.5 mg/kg, 1 mg/kg and 2 mg/kg. The treatments were administered on three consecutive days to achieve final cumulative doses of 1.5, 3 and 6 mg/kg. The control animals were injected i.v. on three consecutive days with ~0.5 ml (2 ml/kg) of vehicle.
Micronucleus assay
Blood for the MN assays was collected from the tail vein of treated rats 24 h after the last X-irradiation, 48 and 72 h after the i.p. treatment with CP and 24 h after the last treatment with Cis-Pt. The blood was fixed and the assays conducted as described in the instructions to the rat MicroFlow kit (Litron Labs, Rochester, NY). Data were collected using a FACSCanto II flow cytometer (BD, Milpitas, CA)
Pig-a assays
For each assay, 100-130 µl blood was collected from each rat by tail vein bleeding. Anticoagulant for the X-ray and CP studies was prepared by reconstituting sodium heparin (Sigma-Aldrich) in neutral PBS at a final concentration of 500 U/ml, sterilising the solution using 0.2-μm filter and storing it at 4°C. Blood for the Cis-Pt experiment was collected using anticoagulant provided in the prototype MutaFlow kit (Litron). For the X-ray and CP experiments, blood was collected through a 25 Ga needle into a 1-ml syringe that was pre-filled with ~350 µl anticoagulant; for the Cis-Pt experiment, blood was collected into an empty syringe, immediately dispensed into an empty 1.5-ml microcentrifuge tube, and then precisely 80 or 100 μl promptly transferred into another microcentrifuge tube pre-filled with an equal volume of anticoagulant.
X-ray experiment.
A basic version of the RBC Pig-a assay, originally described by Dobrovolsky et al. (27) , was used. Six microlitre of anticoagulant-preserved blood was mixed with 200 μl of PBS, 2 μl of fluorescein (FITC)-conjugated anti-rat CD59 antibody (BD) and 0.25 μl of biotinylated anti-erythroid HIS49 antibody (BD). The mixture was incubated for 30 min at room temperature and then labelled with 1 μl of the secondary detection molecule, allophycocyanin (APC)-conjugated streptavidin (BD) and incubated an additional 30 min at room temperature. Two-colour labelled cells were pelleted by centrifugation for 3 min at 300g, resuspended in 1 ml of flow sheath fluid, filtered through 70-μm mesh (to eliminate any aggregated matter that may clog the flow cytometer nozzle) and processed by flow cytometry. Single cells were roughly gated on a forward-versus side-scatter cytogram; single-cell RBCs were identified as the major peak on a HIS49/APC histogram, and CD59-deficient (Pig-a mutant) RBCs were identified by their low FITC fluorescence. The number of mutant RBCs was determined in 700 000-900 000 single-cell RBCs. The gates for HIS49/APC-positive and FITC CD59-negative Pig-a mutant RBCs were determined by running a 'mutant-mimic' sample-blood labelled with HIS49 and APC-streptavidin only. The gate for Pig-a mutants contained at least 98% of single-cell RBCs from the single-colour-labelled 'mutant-mimic' control sample. RBC Pig-a assays were performed 5 days before the first irradiation and at Weeks 1, 2, 3, 5, 6, 8, 9, 12 and 16 after the last irradiation session. In this experiment, RBC Pig-a assays were performed on a FACSAria I flow cytometer (BD) equipped with a 70-μm nozzle and spatially separated 488-nm blue and 635-nm red lasers.
CP experiment. The standard RBC Pig-a assay was scaled up and modified to incorporate the SYTO59 nucleic acid stain (Invitrogen, Carlsbad, CA) for identification of the reticulocyte (RET) fraction among total RBCs. Mutant RETs and mutant total RBCs were determined for individual animals using the same labelled blood sample in two separate flow analyses. Five millimolar SYTO59 was diluted 1:100 with dimethylsulphoxide, aliquoted and stored at −20°C. Thirty microlitres of anticoagulant-preserved blood was mixed with 200 μl of PBS, 4 μl of FITC anti-rat CD59 (BD), 2 μl of diluted SYTO59 (excited by the red laser and detected on the same photomultiplier tube (PMT) as APC is detected) and 1 μl of biotinylated HIS49 antibody; the mixture was incubated at room temperature for 30 min. Three microlitres of the secondary detection molecule, peridinin chlorophyll protein (PerCP)-conjugated streptavidin (BD), was added and the sample was incubated for an additional 30 min, after which the cells were centrifuged for 3 min at 300g, the pellet was resuspended in 1 ml of sheath fluid, filtered through 70-μm mesh, and processed by flow cytometry. Single cells were roughly gated on a forward-versus sidescatter cytogram; white blood cells (WBCs) were eliminated on a SYTO59 histogram as highly fluorescent events (due to their large amount of DNA and RNA); single-cell RBCs were further identified as the major peak on a HIS49/PerCP histogram; CD59-deficient (Pig-a mutant) low FITC fluorescence RETs and normochromatic RBCs were identified on an FITC versus SYTO59 cytogram. Pig-a mutant total RBCs were determined by processing at least 1 000 000 single-cell RBCs; mutant RETs were determined among 100 000-300 000 RETs, contingent upon the concentration of RETs in each sample and the amount of the labelled blood sample remaining after the initial processing for the total RBC Pig-a MF. The gates for HIS49/PerCP-positive and SYTO59-positive (but FITC-negative) Pig-a mutant RETs and mature HIS49/PerCP-positive FITC-negative Pig-a mutant RBCs were determined by running a 'mutant-mimic' control-blood labelled with SYTO59, HIS49 and APC-streptavidin (without labelling with FITC anti-CD59). RBC and RET Pig-a assays were performed 1 day before the treatment of rats with CP and at Weeks 4, 6, 8, 9, 12 and 16 after the treatment. The Pig-a assays were performed on a two-laser FACSAria I flow cytometer.
Cis-Pt experiment. Two high throughput versions of the Pig-a assay utilising magnetic fractionation of blood samples were performed. An assay with enrichment for mutant RBCs, referred to here as the 'HT Litron protocol', was conducted before the treatment and at Weeks 2, 5, 8 and 16. The assay was performed using prototype MutaFlow kits (Litron), and following the manufacturer's suggested protocol as outlined in reference (19) . The other high throughput assay (the PIGRET assay) involved enrichment for the RET fraction of blood samples and was performed as described in reference (18) . The PIGRET assay was performed on a different set of animals, before the treatment and at Weeks 2, 4 and 8. At Week 16, the PIGRET assay was also performed on the remaining animals designated for the analysis using the HT Litron protocol.
Briefly, 80-100 μl of blood was first leucodepleted by centrifugation on a Lympholyte-mammal (Cedarlane, Burlington, NC) density gradient. Then, for the Pig-a mutant enrichment protocol (Litron's protocol), the RBC fraction was labelled with phycoerythrin (PE)-anti-CD59 and PE-anti-CD61 (from the prototype MutaFlow kit), followed by labelling with anti-PE magnetic microbeads (Miltenyi Biotech, Auburn, CA). The labelled RBCs were mixed with magnetically inert CountBright™ absolute counting beads (Invitrogen), with a small fraction of the labelled leucodepleted blood being reserved as a 'pre-column' sample for subsequent flow cytometric analysis. The bulk of the labelled cell and bead mixture was processed on an LS magnetic column (Miltenyi) mounted onto a quadroMACS magnet (Miltenyi). CD59-positive wild-type RBCs, and CD61-positive platelets were retained on the column and the flowthrough fraction, consisting of enriched CD59-deficient (Pig-a mutant) erythrocytes and CountBright beads, was collected as a 'post-column' sample for subsequent flow cytometric analysis. Before the analyses, both the 'pre-' and 'post-column' samples were stained with SYTO13 dye (diluted stock from the prototype MutaFlow kit; SYTO13 is manufactured by Invitrogen). Following flow cytometric analysis, total RBC and RET Pig-a MFs were calculated from the cell equivalents analysed using the ratios of the CountBright beads to total RBCs and RETs in the 'pre-column' sample and the ratios of CountBright beads to enriched mutant RETs and mutant total RBCs in the 'post-column' sample for each animal. Litron's instructions for use of the prototype kit and analysis of the samples were followed strictly, including making appropriate instrument calibration samples and setting compensation parameters. The analysis was performed on a FACSCanto II flow cytometer (BD) equipped with 488-and 635-nm lasers. Counting beads were identified by 635-nm red laser-induced fluorescence detected on a PMT equipped with a 660/20 filter. Currently, Litron recommends a modified magnetic enrichment protocol, with the counting beads not passing through the magnetic column.
For the PIGRET assay, the leucodepleted RBCs were labelled with PE-anti-CD71 (BD), then with anti-PE BD IMag™ magnetic particles (BD). Magnetically labelled CD71-positive RETs were selectively retained using an IMag magnet (BD) and following the manufacturer's suggested protocol. RET Pig-a MFs were determined by flow cytometry using the enriched fraction of CD71-positive cells. The enriched RETs were labelled with FITC-anti-CD59, biotinylated HIS49 antibody and later with APC-streptavidin for positive detection of RBCs. Mutant RETs were PE-CD71-positive, HIS49/APCpositive and FITC-anti-CD59-negative. Wild-type RETs were FITC-, PE-and APC-positive.
Pig-a MFs for total RBCs in the PIGRET assay were determined in separate labelling reactions using unprocessed heparin-preserved whole blood in a procedure similar to the one used in the X-ray experiment. The equivalent of 3 μl of raw blood (6 μl of 1:1 mixture of blood:anticoagulant) was labelled with FITC-anti-CD59, biotin-HIS49 and later with APC-streptavidin. Pig-a MFs were calculated as a ratio of FITC-negative, APC-positive single cells to the total number of APC-positive single RBCs. Both the PIGRET assay and the assay for Pig-a mutant total RBCs were performed on a 2-laser FACSAria I. Table I summarises the rat erythrocyte Pig-a assays that were performed in this study, and includes technical details on the number of cells interrogated and the perceived advantages and disadvantages of each assay.
Hprt assay T-cell Hprt mutation assays were performed similarly to those previously described for mice (28) . Briefly, animals were euthanised by CO 2 , and their spleens were crushed to release stored peripheral RBCs and WBCs. WBCs were fractionated by centrifugation on a Lympholyte-R (Cedarlane) density gradient, stimulated overnight into proliferation with the mitogen, concanavalin A, and seeded into 96-well plates in culture medium promoting T-cell growth, either in the presence of 6-thioguanine (6-TG) for selection of mutants or without 6-TG for determining cloning efficiency. After 12 days in culture, the viability indicator alamarBlue (Trek Diagnostics, Cleveland, OH) was added to all wells of all plates for 24 h, the wells containing developing clones were identified with the help of a fluorescence plate reader, and the frequencies of Hprt mutant lymphocytes were calculated. The Hprt mutation assays were performed at Weeks 3, 6, 9 and 16 after the last irradiation or the treatment with CP, or at Weeks 2, 4, 8 and 16 after the treatment with Cis-Pt.
Statistical analyses
Raw data were processed using the SigmaPlot v11 program (Systat Software, Chicago, IL). When data were available only for two groups, a t-test or MannWhitney test was used for comparing the values. When data were available for more than two groups, differences between the groups were analysed using one-way analysis of variance (ANOVA) or ANOVA on ranks, followed by multiple comparisons between each treated group and the vehicle control group [Dunnett's method (when available) or Dunn's method]. A P value of <0.05 was chosen to indicate statistically significant difference between the groups; all tests were two-tailed.
Results
General animal welfare
The numbers of animals in the control and high-dose treatment groups were greater than in the low-and medium-dose-treatment groups. The control and high-dose groups decreased over time because five animals from these groups were removed for determining the frequency of Hprt mutant lymphocytes at three time points before the final analysis of Hprt mutation in animals from all treatment groups at Week 16 (see Figure 1) .
All treatments were administered at non-lethal doses although the high doses were anticipated to approach the maximum tolerated dose; no animals died over the observation period of 16 weeks after the exposures. Almost all treated animals initially lost weight and decreased their activity. Low-and mediumdose-treated rats returned to their pre-exposure weights by Week 2 post-exposure. High-dose-treated animals returned to pre-exposure weights by Week 3 post-exposure, after which all treated animals continued gaining weight.
MN results
Exposure to X-rays, CP and Cis-Pt induced increases in the percent of micronucleated reticulocytes (%MN RETs) in the peripheral blood (see Figure 2) . In irradiated animals, the %MN RETs were dose related at 24 h after the last exposure session, with a corresponding decrease in the fraction of RETs (%RETs). In the same animals, there was no evidence of DNA damage when measured 1 week after the last irradiation: the %MN RETs in radiation-treated animals was no different than in control animals (data not shown). The %MN RET frequency also was increased 48 h after the exposure to CP, without any apparent relationship to the dose ( Figure 2) ; the fraction of RETs also was decreased in high-dose and medium-dose animals and to a lesser extent in low-dose-treated animals. At 72 h after administration of CP, %MN RETs increased even further (to ~4% in animals treated with 40 mg/kg and 2.6% in animals treated with 80 mg/kg); however, at the same time, the %RETs in the medium-and high-dose-treated animals decreased to ~1% of the vehicle control, making the measurement of MN frequencies unreliable (not shown in Figure 2 ). In Cis-Pttreated animals, a clear dose-related increase in %MN RETs was observed 24 h after the last administration of the test compound ( Figure 2) . Overall, the immediate toxic effect of exposure to bone marrow (measured as %RETs drop) was most pronounced in CP-treated animals.
Pig-a MF results
The frequency of Pig-a mutant RBCs (and RETs in some experiments) was measured in all animals before the treatments (Figure 3 ). These frequencies were uniformly low (~5 × 10 -6 or less) in all animals. In control groups (unirradiated animals and the animals treated with vehicle solutions), the frequency of Pig-a mutant RBCs and RETs was consistently low over the course of the experiments, with minimal variation from one measuring time to another.
In X-ray-exposed animals, the frequency of CD59-deficient Pig-a mutant RBCs was highly variable within each treatment group. In some individual animals the treatments had a minimal effect on the Pig-a RBC MF, whereas in other animals the frequency of Pig-a mutant RBCs increased transiently, returning to near background values by 16 weeks after the treatment. Over the monitoring period, 5 animals (out of 20) exposed to the high dose of X-rays and 1 animal each in the low-and medium-dose groups displayed Pig-a MFs above 20 × 10 -6 , with a trend indicating the potential to increase further. Animals treated with 3 Gy and showing the highest responses in the Pig-a assay were pre-scheduled for the Hprt assay at intermediate time points, so that the Pig-a MF was not determined for these animals at later time points. Because many of these high-responding animals were sacrificed at earlier time points, the overall MF in 3 Gy animals at Week 16 was close to background. The prescheduled intermediate sacrifices, however, did not remove the higher trending 1 Gy-and 2 Gy-exposed animals. The high responders from these groups were carried to the end of the experiment (when their Pig-a MFs were the highest), but the other animals in these groups returned to near background MFs by Week 16. At Week 16 post-exposure, the total RBC Pig-a MFs in the animals remaining for assay in the treatment groups was not statistically different than the vehicle control.
Pig-a MF did not exceed 14 × 10 -6 in any CP-treated rat over the entire monitoring period. By Week 2 after the acute treatment, all CP-treated animals showed a significant rebound in erythropoiesis as was evidenced by an unusually high fraction of SYTO59-positive RETs with uncharacteristically strong nucleic acid labelling (compared with control animals). This surge in erythropoiesis coincided with high variability in the frequency of CD59-deficient RBCs and inconsistent labelling of the RET fraction. Elevated frequencies of CD59-negative RETs at Weeks 1 and 2 were not followed by elevated frequencies of CD59-deficient total RBCs at later time points. Thus, data determined at early time points after treatment with CP were deemed unreliable and they are not presented here.
Clear increases in CD59-deficient Pig-a mutant RETs and total RBCs were detected beginning at Week 2 after treatment with Cis-Pt (Figure 3 ). The two high throughput versions of the assay produced similar results for the background RET MF in control animals (MF ~5 × 10 -6 ) and the maximum RET MF in the high-dose animals (~25 × 10 -6 ). Compared with the PIGRET assay, enrichment for mutants (HT Litron's protocol) resulted in lower MFs for total RBCs in control animals at all measured time points (~2 × 10 -6 vs. ~5 × 10 -6 using the PIGRET protocol) and in slightly lower MFs for the high dose-treated animals (e.g. ~20 × 10 -6 vs. ~25 × 10 -6 at Week 8 after treatment). All the animal-by-animal Pig-a MFs determined in this study are given in Supplementary Table 1, available at Mutagenesis Online.
Hprt MF results
Lymphocyte Hprt MFs were measured in control and high-dosetreated animals at several intermediate times post-exposure, and only once in all treated animals at the end of the experiments at . For X-rays and Cis-platin (Cis-Pt), MN data were determined 24 h after the last treatment. For X-rays and cyclophosphamide, the fraction of MN RETs was determined out of the sample of 20 animals (5 animals per each group), although more animals were employed in each experiment. For Cis-Pt, the fraction of MN RETs was determined in all 54 animals. For cyclophosphamide experiment, the data were shown for blood collected 48 h after the acute treatment; at 72 h, the average fraction of MN RETs was even higher, yet the overall fraction of reticulocytes was severely decreased, so that recommended number of cells could not be processed from individual animals. **different from vehicle control animals (ANOVA, P < 0.05).
Week 16 (Figure 4) . At all measured time points, Hprt MF was elevated in high-and medium-dose-treated animals (radiation, CP and Cis-Pt). In absolute values and in relative-to-control fold-increases, radiation was more efficient than CP or Cis-Pt in inducing Hprt mutation. Outliers were noted among the CPand Cis-Pt-treated animals, which decreased the significance of comparisons with the control. These outliers exhibited Hprt MFs exceeding the average for the remaining animals in the group by more than 3 SD and were discarded from statistical analyses. Outliers were not present in vehicle control groups.
Discussion
In the current series of experiments, we have evaluated the ability of the recently developed Pig-a assay for detecting the in vivo mutagenicity of three known clastogens, X-rays, CP and Cis-Pt. We have compared the responses produced by these clastogens in the Pig-a assay with the responses produced in two other more established in vivo assays-the RET MN assay, a common in vivo assay for regulatory safety assessments and the less frequently used lymphocyte Hprt gene mutation assay.
The performance of the Pig-a assay has been of particular interest for regulatory genetic toxicology. Because it does not rely on transgenic animals and does not require cell culture, the Pig-a assay is easier and less expensive to conduct than other in vivo gene mutation assays (20) . Also, because it requires only small volumes of peripheral blood, it can be integrated into 28-day repeat dose general toxicology assessments, where it wouldn't require additional animals, but would refine the overall toxicity assessment by providing additional valuable information (21) .
Both the Hprt and the Pig-a genes are located on the X-chromosome, which should make their properties for detecting mutation similar and limit their ability to detect loss of heterozygosity mutations. Nevertheless, these two genes reside at different loci on the X-chromosome, which may factor into their ability to detect different types of mutation. For instance, sequencing of DNA from PNH patients suggests that diseaseassociated inactivation of the PIG-A gene is predominantly due to small intragenic mutations, such as frameshifts and base-pair substitutions (29) (30) (31) . Large deletions affecting the entire gene are not common. If the same is true for rodents, then large deletions induced by clastogens may not be recoverable in rodent Pig-a assays. In contrast, the Hprt gene is known to recover large deletions (32) . Also, mutation induction in the Pig-a assay is currently limited to erythroid precursor cells in the bone marrow (18, 33) . On the other hand, mutations detected in the Hprt lymphocyte assay may be induced in the bone marrow (34) and in other compartments on the transit to periphery (e.g. thymus and spleen), especially if the treatment provided some proliferative stimulus. This formed the basis for our working hypothesis that the Hprt lymphocyte assay may be more sensitive than the erythrocyte Pig-a assay for detecting gene mutation produced by clastogenic treatments. Fig. 3 . RBC Pig-a gene mutation assays. Average frequency of CD59-deficient total RBCs (squares) or reticulocytes (circles) are shown for each datapoint. Error bars are not shown in order to avoid congestion. *different than vehicle control (t-test, P < 0.05); **different than vehicle control (ANOVA, P < 0.05). Cis-Pt: at 16-week time point, blood from animals designated for mutant enrichment (Litron's protocol) also was processed using reticulocyte enrichment protocol; the results produced by the two protocols were similar in terms of the magnitude of the response and the statistical significance (data not shown). Note that in X-rays, cyclophosphamide and Cis-Pt/PIGRET experiments, the number of animals representing average value for the controls and the high-dose-treated animals at different time points is decreasing due to sampling of five vehicle control-and five high-dose-treated animals for the Hprt assay at specific times (see Figure 1) . In Cis-Pt experiment, the number of animals analysed using the Litron enrichment protocol remained the same at all time points.
Although all three clastogens were positive in both the Pig-a and Hprt assays, the Hprt assay appeared to produce stronger and more consistent responses than the Pig-a assay for X-rays and CP. With Cis-Pt, the situation was somewhat different, with the Pig-a assay producing equal or slightly higher induced MFs than the Hprt assay. Because the Pig-a assay has a lower background mutant frequency than the Hprt assay, a higher fold increase was observed in the Pig-a assay in Cis-Pt-treated animals.
In our study, X-rays were a strong inducer of MN RETs, yet a fairly inconsistent inducer of the mutation in the Pig-a gene as measured in total RBCs. The transient increase of CD59-deficient cells in exposed rodents may indicate that an underlying large deletion mutation affecting the Pig-a gene might have developed in short-lived differentiating (nucleated) erythropoietic cells that produced a surge of mutant RBCs. If this interpretation is correct, this large deletion may be incompatible with the survival of erythropoietic stem cells. In the few animals in which the frequency of CD59-deficient cells was elevated for an extended period of time, the underlying (presumably small) mutation within the Pig-a gene might have originated in early erythropoietic precursors capable of sustained production of mutant RBCs. Similar observations were noted in experiments measuring Pig-a mutation in irradiated mice (i.e. transient increase in the frequency of mutant cells) (35) .
Previous experiments in Kasahara's group suggest that CP is not efficient in inducing Pig-a mutation in rats (36) . CP produces the most toxic type of DNA damage-the interstrand crosslink (37) , which is a very strong clastogen. In our study, CP treatment increased the frequency of CD59-deficient cells, it was clearly observed only in total RBCs, and the increase was transient. The absence of animals with sustained elevated frequencies of CD59-deficient mutant cells suggests that the major type of DNA alteration produced by CP was not compatible with the survival of erythroid precursor cells, as may be the case for X-rays.
Our RET version of the Pig-a assay was not very useful for detecting the mutagenicity of CP, especially when measured at early time points. The surge in erythropoiesis produced by CP exposure increased the frequencies of CD59-deficient RETs in some animals without increasing total RBC MFs at later time points. It is known that stimulating erythropoiesis can result in increased frequencies of MN RBCs in the absence of true genotoxicity (38) . This raises the question of whether a similar phenomenon might occur for gene mutation. It is possible that the surge in erythropoiesis that occurred after the acute CP treatment resulted in the production of defective RETs that were deficient in GPI or anchored-marker(s) but without mutations in genes of GPI synthesis pathway. Those defective RBCs might be eliminated from circulation through a mechanism similar to the one that efficiently eliminates circulating MN cells in rats. On the other hand, the erythropoiesis stimulated in animals by regenerative anaemia does not result in increased Pig-a mutant RBC or RET frequencies (39) .
Recently, Dertinger et al. (40) have described a version of the Pig-a assay that uses magnetic enrichment for mutant cells in order to more precisely measure weak responses. Using this methodology, they also have observed a somewhat modest (in absolute values) induction of CD59-deficient Pig-a mutant RBCs in rats treated with CP for 3 and 28 days, with apparently more stability in the MFs than we found (41) .
Cis-Pt, being a crosslinker similar in action to CP, was expected to induce a similarly weak response in the Pig-a assay. Therefore, we used the Litron protocol for enrichment of mutants using normalising counting beads that were processed through the magnetic columns; we also used an enrichment Fig. 4 . Hprt gene mutation assay. Average and standard deviations (as error bars) are shown for each datapoint. X-rays: for 9-week time point, one outlier in the 3 Gy dose group was discarded; for 16-week time point, one outlier from the 3 Gy dose group and one outlier from the 2 Gy dose group were discarded. Cyclophosphamide: for the 16-week time point, one outlier in the 10 mg/kg group and one outlier in the 40 mg/kg group were discarded. Cis-Pt: for the 16-week time point, one outlier in the 6 mg/kg group was discarded. All outliers had much elevated frequency of 6-TG-resistant clones. Note that due to elimination of animals, different number of animals may constitute a datapoint at different time points. *different from the vehicle control (t-test, P < 0.05); **different from vehicle control group (ANOVA, P < 0.05). method previously developed by Kimoto et al. (PIGRET assay) , in which normalising beads are not used. The Litron and the PIGRET assays produced similar results. Of the three agents used for this study, Cis-Pt produced by far the greatest, and most stable, Pig-a responses, and it is arguable whether the increased power afforded by these more labour-intensive enrichment assays was necessary for adequately describing the mutagenicity of Cis-Pt.
Other observations indicate that Cis-Pt may be the overall best in vivo gene mutagen of the three agents assayed in our study. For instance, Cis-Pt also induced gene mutation in the Muta mouse assay (42) , and of the patients monitored for PIG-A mutation in our previous study, those whose treatment included Cis-Pt had the greatest increases in MF (5). The in vivo genotoxicity of Cis-Pt may be influenced by the types of crosslinks formed by Cis-Pt (intrastrand and interstrand) and monoadducts.
Finally, our Cis-Pt study also provided the first direct comparison of Pig-a MFs generated by the two major magnetic enrichment methods that have been described, the HT Litron protocol and the PIGRET assay. It was noticed that the HT Litron protocol utilising enrichment for mutants (employing counting beads for normalisation purposes) results in almost identical calculated Pig-a MFs as generated in the PIGRET protocol without using normalising beads. Given the complexity of these two protocols, however, additional comparative studies will be necessary to confirm whether the methodological differences have a practical impact on detecting in vivo gene mutation.
In conclusion, gene mutation is a valuable endpoint in safety evaluations: it informs on the long-term consequences of exposure to potential DNA-reactive compounds. But the choice of the best (most sensitive and/or most practical) methodology for assessing gene mutation caused by clastogens may depend upon the nature of the agent and may not be obvious, especially, when studying novel compounds (e.g. pharmaceuticals). The results of our study indicate that both the RBC Pig-a assay and lymphocyte Hprt assay are capable of detecting the in vivo mutagenicity of radiation, and of two DNA crosslinkers, albeit with different degrees of sensitivity. But because the Pig-a assay is minimally invasive, can be performed on standard rat strains, and is reasonably affordable, it may function as a useful assay, even though it may not be the most sensitive gene mutation assay for every agent. 
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